Eli Lilly Drug Shows New Potential in Curbing Food CravingsEli Lilly’s GLP-1 weight-loss drug tirzepatide — sold as Mounjaro and Zepbound — may do more than suppress appetite. A new Nature Medicine report shows that in one patient with severe binge-eating behavior, the drug appeared to silence food-craving signals in the brain’s reward center. This is the f
Key facts today
Eli Lilly's weight-loss drug, orforglipron, showed a 10.5% weight loss in overweight type 2 diabetes patients over 72 weeks, with regulatory approval expected by year-end.
Eli Lilly's stock has increased by 40% this year, contributing to an addition of more than $400 billion in market value since early August 2025.
Eli Lilly's GLP-1 drugs, Zepbound and Mounjaro, are being evaluated for preventing Alzheimer's, especially after Novo Nordisk's Rybelsus trials failed, leading to calls for more research.
0.30 USD
9.41 B USD
40.01 B USD
About Eli Lilly and Company
Sector
Industry
CEO
David A. Ricks
Website
Headquarters
Indianapolis
Founded
1876
ISIN
ARDEUT111192
FIGI
BBG000HFTTN7
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Related stocks
Eli Lilly Hits $1 Trillion Milestone on GLP-1 BoomEli Lilly & Co. (NYSE: NYSE:LLY ) briefly crossed the $1 trillion market-cap threshold, becoming the first health-care company in history to reach the valuation. Shares traded around $1,059 as demand for its GLP-1 weight-loss and diabetes drugs exploded, driving extraordinary revenue growth and sol
Eli Lilly’s $1T Breakout at 1060 | End of the Supercycle?Eli Lilly (LLY) – Macro Elliott Wave, Fibonacci & Historic $1 Trillion Milestone
LLY has now reached a critical long-term inflection point, advancing directly into the 2.618 Fibonacci extension , completing the projection of a full five-wave Elliott Wave cycle. This precise alignment establis
Eli Lilly: The Trillion-Dollar Cure for Market Volatility?Eli Lilly has officially shattered the Silicon Valley ceiling, becoming the first healthcare company to achieve a $1 trillion market capitalization. While tech giants like Nvidia grapple with bubble concerns and doubts about AI monetization, Lilly has delivered tangible, recurring revenue through it
ELI LILLY to soon start a correction towards $700.Eli Lilly (LLY) has made new All Time Highs (ATH) this month, extending the impressive rally since the August Low near the 1W MA200 (orange trend-line).
The multi-year trend remains bullish within a Fibonacci Channel Up but practically the stock hasn't gotten out of its range since the July 2024 Hi
"LLY's Bear Market Mode ON | Crash Incoming"“ LLY is gearing up for a sharp correction down to the $35–$17 zone — a critical reset that could flush out weak hands before the next explosive bull run. Stay sharp, this is where big opportunities form. ⚠️
🔥 Summary:
Eli Lilly (LLY) looks ready for a major market reset after completing a
Eli Lilly Testing $1000 — Breakout or Fakeout?After consolidating for over a year inside a descending channel, LLY has rallied back to the top resistance zone around $1000.
Bullish Case:
• Breakout above $1000 = start of new uptrend.
• Targets: $1100 → $1200.
Bearish Case:
• Rejection at $1000 could pull price back to $850–$800, or eve
Eli Lilly and Company: Path to Sustained Market LeadershipEli Lilly and Company has achieved a market valuation approaching one trillion U.S. dollars by the close of 2025, underpinned by a comprehensive corporate strategy that integrates advanced scientific research, targeted technology acquisitions, and adaptive global partnerships. This performance, mark
$LLYThe technical structure for NYSE:SMR presents a compelling case of a strong, sustained uptrend, characterized by a rhythmic pattern of sharp advances followed by periods of consolidation. This behavior is the hallmark of a healthy, momentum-driven bull move.
1. Pattern Analysis: Sequential Bull F
See all ideas
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
XS238628644
Eli Lilly and Company 1.625% 14-SEP-2043Yield to maturity
5.69%
Maturity date
Sep 14, 2043
LLY4099975
Eli Lilly and Company 4.65% 15-JUN-2044Yield to maturity
5.65%
Maturity date
Jun 15, 2044
US532457BU1
Eli Lilly and Company 4.15% 15-MAR-2059Yield to maturity
5.53%
Maturity date
Mar 15, 2059
LLY6003397
Eli Lilly and Company 5.6% 12-FEB-2065Yield to maturity
5.49%
Maturity date
Feb 12, 2065
LLY6153503
Eli Lilly and Company 5.65% 15-OCT-2065Yield to maturity
5.46%
Maturity date
Oct 15, 2065
LLY5871804
Eli Lilly and Company 5.2% 14-AUG-2064Yield to maturity
5.46%
Maturity date
Aug 14, 2064
LLY5750032
Eli Lilly and Company 5.1% 09-FEB-2064Yield to maturity
5.45%
Maturity date
Feb 9, 2064
LLY5547405
Eli Lilly and Company 4.95% 27-FEB-2063Yield to maturity
5.43%
Maturity date
Feb 27, 2063
US532457BY3
Eli Lilly and Company 2.25% 15-MAY-2050Yield to maturity
5.43%
Maturity date
May 15, 2050
LLY6153502
Eli Lilly and Company 5.55% 15-OCT-2055Yield to maturity
5.37%
Maturity date
Oct 15, 2055
LLY5871803
Eli Lilly and Company 5.05% 14-AUG-2054Yield to maturity
5.36%
Maturity date
Aug 14, 2054
See all LLYC bonds













